Relevant bibliographies by topics / Multiple myeloma; Breast cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Multiple myeloma; Breast cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Multiple myeloma; Breast cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Multiple myeloma; Breast cancer"

1

Gulmez, Ahmet. "Breast cancer after multiple myeloma treatment." Current Problems in Cancer 43, no. 6 (2019): 100463. http://dx.doi.org/10.1016/j.currproblcancer.2019.01.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Savage, David, and T. J. Garrett. "Multiple myeloma masquerading as metastatic breast cancer." Cancer 57, no. 5 (1986): 923–24. http://dx.doi.org/10.1002/1097-0142(19860301)57:5<923::aid-cncr2820570507>3.0.co;2-u.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ali, Heba O. E., Zafar Nasir, and Ahmed M. S. M. Marzouk. "Multiple Myeloma Breast Involvement: A Case Report." Case Reports in Radiology 2019 (October 9, 2019): 1–5. http://dx.doi.org/10.1155/2019/2079439.

Full text
Abstract:
Multiple Myeloma involving the breast is very rare and the diagnosis is challenging because the clinical and radiological features of breast multiple myeloma are indistinguishable to other forms of breast disease whether primary or metastatic. In this article the authors report a case presented with breast masses, which were found to be extra osseous Multiple Myeloma. The patient was managed for multiple spinal lesions that were primarily thought to be metastasis from primary breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
4

Al-Said Ali, Ali, Ibtisam Al-Bader, Fatma Al-Ali, Abdel Hamid Elgazzar, and Salah Fayez. "Breast Cancer and Multiple Myeloma at Initial Presentation." Breast Journal 15, no. 1 (2009): 103–5. http://dx.doi.org/10.1111/j.1524-4741.2008.00679.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Evens, Andrew M., June M. McKoy, Paul R. Yarnold, Kathyrn McCaffrey, and Charles L. Bennett. "Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide’s “Off-Label” Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns." Blood 106, no. 11 (2005): 2244. http://dx.doi.org/10.1182/blood.v106.11.2244.2244.

Full text
Abstract:
Abstract Purpose: In 1999, one year after its approval by the FDA for erythema nodosum leprosum, thalidomide’s effectiveness as an off-label treatment for multiple myeloma was noted. A 28% rate of thromboembolism with thalidomide-doxorubicin therapy for myeloma was reported in 2001. Thalidomide’s inclusion in the 2004 Medicare Oral Pharmaceutical Demonstration Project as treatment for multiple myeloma represents the only off-label use drug covered. FDA regulations prohibit manufacturer dissemination of comprehensive safety information describing thalidomide-associated thromboembolism (TAT) in
APA, Harvard, Vancouver, ISO, and other styles
6

YONEYAMA, Kimiyasu, Shigehiro KIKUYAMA, and Renpei OOYAMA. "A CASE OF BREAST CANCER COMPLICATED BY MULTIPLE MYELOMA." Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 67, no. 12 (2006): 2796–99. http://dx.doi.org/10.3919/jjsa.67.2796.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hough, Bruce, Adam Brufsky, and Suzanne Lentzsch. "Metastatic Breast Cancer or Multiple Myeloma? Camouflage by Lytic Lesions." Journal of Oncology 2010 (2010): 1–3. http://dx.doi.org/10.1155/2010/509530.

Full text
Abstract:
We report a case of a female with stage I infiltrating ductal carcinoma who received adjuvant therapy including trastuzumab. One year later she developed lytic lesions and was retreated with trastuzumab that was held after she developed symptomatic heart failure. Lytic lesions were attributed to relapse of breast cancer, and cardiac failure attributed to prior trastuzumab therapy. After complications necessitated multiple hospitalizations, a further workup revealed that the lytic lesions were not metastatic breast cancer but multiple myeloma. Her advanced multiple myeloma was associated with s
APA, Harvard, Vancouver, ISO, and other styles
8

Durusu, Mine, M. Kadri Altundağ, Duygu Yazgan Aksoy, Hüseyin Abali, Alev Türker, and Arzu Sungur. "Metastatic Carcinoma of the Breast Mimicking Multiple Myeloma." Tumori Journal 89, no. 1 (2003): 106–7. http://dx.doi.org/10.1177/030089160308900124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dorantes-Heredia, Rita, Daniel Motola-Kuba, Jose Manuel Ruiz-Morales, Wallace Rafael A. Muñoz-Castañeda, Carolina Vega-Ochoa, and Roberto De la Peña. "Searching for the Culprit: Metastases from a Cancer of Unknown Primary." Case Reports in Oncology 11, no. 2 (2018): 541–48. http://dx.doi.org/10.1159/000491600.

Full text
Abstract:
We report a case of metastases from a cancer of unknown primary whose primary site could not be identified during the appropriate pretreatment evaluation. The patient was a 58-year-old woman with a history of passive smoking and with no history of cancer in the family. Her current condition started with asthenia, adynamia, and pallor, followed by palpitations. An abdominopelvic computed tomography (CT) scan was performed, showing multiple osteolytic lesions distributed in all bone structures and axillary adenopathy on the left side. As part of the approach and given the high suspicion of multi
APA, Harvard, Vancouver, ISO, and other styles
10

Lage, M., D. J. Harrison, B. Barber, and S. Jun. "Burden of hospitalizations associated with skeletal related events in patients with breast cancer or lung cancer and bone metastases or multiple myeloma." Journal of Clinical Oncology 25, no. 18_suppl (2007): 17083. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.17083.

Full text
Abstract:
17083 Background: Patients with bone metastases secondary to cancer often experience skeletal related events (SREs) including pathological fracture, spinal cord compression, hypercalcemia, bone surgery or radiotherapy, or initiation of opioid analgesic use. These SREs result in major morbidity and reduced quality of life. This research examines hospitalizations associated with SREs. Methods: Data for this study were obtained from i3 LabRx Database (05/01/2000 to 03/31/2005). Individuals were included in the analyses if they had at least two diagnoses of breast cancer (based upon an ICD-9 code
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Multiple myeloma; Breast cancer"

1

Drake, Mary. "Characterisation of mononuclear cells in peripheral blood stem cell harvests." Thesis, Queen's University Belfast, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.287206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Harrison, Simon James. "Immunotherapy in multiple myeloma." Thesis, University of Glasgow, 2005. http://theses.gla.ac.uk/1054/.

Full text
Abstract:
The BDCA antibodies allowed reliable measurement of dendritic cell (DC) subsets and B cell numbers in the blood of normal subjects, and patients with MM throughout the disease course. The numbers of blood myeloid DC (BmDC) and blood plasmacytoid DC (BpDC) are low throughout the course of the disease, and only improve for a short period of time following autologous HSCT. Thalidomide therapy of patients with relapsed disease was associated with an increase in BmDC1 and BpDC numbers. Monocytes, mobilised at the time of stem cell collection, were used to produce mature DC (matDC) from MM patients
APA, Harvard, Vancouver, ISO, and other styles
3

Dimberg, Lina. "Apoptosis Regulation in Multiple Myeloma." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mhadgut, Hemendra M. D., Alay Mansurov, Rabia Zafar, and Koyamangalath Krishnan. "Liver Mass: An Unusual Presentation of Multiple Myeloma." Digital Commons @ East Tennessee State University, 2020. https://dc.etsu.edu/asrf/2020/presentations/22.

Full text
Abstract:
Multiple myeloma is characterized by proliferation of plasma cells in the bone marrow, producing monoclonal immunoglobulin. It accounts for 17% of hematologic malignancies in the US. Diagnosis is often suspected in the setting of bone lytic lesions, anemia, hypercalcemia or renal failure. Rarely, multiple myeloma can present with soft tissue involvement which can be difficult to diagnose. Below we present one such presentation. Our patient is a 53-year-old who was initially diagnosed with multiple myeloma six years back when he presented to hospital with back and right leg pain. On admission h
APA, Harvard, Vancouver, ISO, and other styles
5

Cook, Gordon. "Immune regulation in multiple myeloma : the host-tumour conflict." Thesis, University of Glasgow, 2000. http://theses.gla.ac.uk/6140/.

Full text
Abstract:
The data presented in this thesis demonstrates that the malignant plasma cells of multiple myeloma are capable of suppressing the activation of T lymphocytes. The myeloma cells prevent activation of T cells from healthy donors by allo-antigen, mitogen and IL-2, mediated by the production of soluble, immuno-suppressive factor. This factor was responsible for inducing cell cycle arrest and failure of the T cells to progress into the autocrine IL-2 autocrine pathway, which is of critical importance in the activation of T cells. To further investigate this interaction an in vitro model system was
APA, Harvard, Vancouver, ISO, and other styles
6

Okumura, Setsuko. "Feasibility of breast-conserving therapy for macroscopically multiple breast cancer." Kyoto University, 2004. http://hdl.handle.net/2433/147559.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Faiman, Beth Marie. "Peripheral Neuropathy and Diarrhea Symptoms in Multiple Myeloma." Case Western Reserve University School of Graduate Studies / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=case1417619492.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Machin, Reinaldo Franqui. "Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma." Diss., University of Iowa, 2018. https://ir.uiowa.edu/etd/6104.

Full text
Abstract:
Multiple Myeloma (MM) is an incurable plasma cell malignancy and, although novel treatment regimes in the past decade have improved patient outcome, long-term treatment leads to relapse and refractory disease. The centrosomal kinase NEK2 is found overexpressed in MM and promotes chromosomal instability, drug resistance and increased proliferation. Although much research shows NEK2 having a detrimental effect in cancer, much of its mechanisms of overexpression and drug resistance has not been studied in detail. In this work we expand our understanding of NEK2 in MM. Using Tandem Affinity Purifi
APA, Harvard, Vancouver, ISO, and other styles
9

Zabalo, Joaquin. "A Mathematical Model Describing the Early Development of Multiple Myeloma." Scholarly Repository, 2010. http://scholarlyrepository.miami.edu/oa_dissertations/366.

Full text
Abstract:
Multiple myeloma is a malignant bone marrow plasma cell tumor which is responsible for approximately 12,000 deaths per year in the United States and two percent of all cancer deaths. It is recognized clinically by the presence of more than ten percent bone marrow plasma cells, the detection of a monoclonal protein (M-protein), anemia, hypercalcemia, renal insufficiency, and lytic bone lesions. The disease is usually preceded by a premalignant tumor called monoclonal gammopathy of undetermined significance (MGUS), which is present in one percent of adults over the age of fifty, three percent ov
APA, Harvard, Vancouver, ISO, and other styles
10

Kendrick, Felicity. "Modelling immunoglobulin metabolism and its effect on prognostic utility in multiple myeloma." Thesis, University of Warwick, 2018. http://wrap.warwick.ac.uk/104030/.

Full text
Abstract:
Multiple myeloma is a cancer of plasma cells. In multiple myeloma, a clone of plasma cells in the bone marrow secretes a unique, monoclonal immunoglobulin (Ig), whose biological properties depend on its type and structure. The monoclonal Ig offers a convenient opportunity for clinicians to monitor the response of the tumour to therapy via the secreted protein, which is readily quantified in a blood sample. Responses to treatment are assigned based on the percentage reduction in monoclonal Ig; however, response criteria do not take into account the different metabolic half-lives of the proteins
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Multiple myeloma; Breast cancer"

1

Dancing with cancer: A healing through visualization. Noteman Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wagner, John R. Thirty and terminal: Cancer survival. Infinity Pub., 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hayat, M. A. Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary tract Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Springer Science+Business Media B.V., 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

GOVERNMENT, US. An Act to Amend the Public Health Service Act to Provide for Research, Information, and Education with Respect to Blood Cancer. U.S. G.P.O., 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gearin-Tosh, Michael. Living proof: A medical mutiny. Scribner, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gearin-Tosh, Michael. Living proof: A medical mutiny. Scribner, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Foote, MaryAnn, G. Molineux, and Tara Arvedson. Twenty years of G-CSF: Clinical and nonclinical discoveries. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Peter, Gale Robert, Juttner Christopher, and Henon P. R, eds. Blood stem cell transplants. Cambridge University Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gasparetto, Christina, and Dharshan Sivaraj. Understanding Multiple Myeloma. Jones & Bartlett Learning, LLC, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jerome E., Ph.d. Tanner. Myeloma (The Biology of Cancer). Chelsea House Publications, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Multiple myeloma; Breast cancer"

1

Workman, Paul. "Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective." In Advances in Experimental Medicine and Biology. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-40204-4_11.

Full text
Abstract:
Abstract This personal perspective focuses on small-molecule inhibitors of proteostasis networks in cancer—specifically the discovery and development of chemical probes and drugs acting on the molecular chaperones HSP90 and HSP70, and on the HSF1 stress pathway. Emphasis is on progress made and lessons learned and a future outlook is provided. Highly potent, selective HSP90 inhibitors have proved invaluable in exploring the role of this molecular chaperone family in biology and disease pathology. Clinical activity was observed, especially in non small cell lung cancer and HER2 positive breast cancer. Optimal use of HSP90 inhibitors in oncology will likely require development of creative combination strategies. HSP70 family members have proved technically harder to drug. However, recent progress has been made towards useful chemical tool compounds and these may signpost future clinical drug candidates. The HSF1 stress pathway is strongly validated as a target for cancer therapy. HSF1 itself is a ligandless transcription factor that is extremely challenging to drug directly. HSF1 pathway inhibitors have been identified mostly by phenotypic screening, including a series of bisamides from which a clinical candidate has been identified for treatment of ovarian cancer, multiple myeloma and potentially other cancers.
APA, Harvard, Vancouver, ISO, and other styles
2

Gullo, Charles A. "Multiple Myeloma." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_3898.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gullo, Charles A. "Multiple Myeloma." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_3898-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gullo, Charles A. "Multiple Myeloma." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-46875-3_3898.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wadhwa, Shilpi, David Y. Johnson, and Frank E. Johnson. "Multiple Myeloma." In Patient Surveillance After Cancer Treatment. Humana Press, 2012. http://dx.doi.org/10.1007/978-1-60327-969-7_98.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dicato, Mario A. "Multiple Myeloma." In Side Effects of Medical Cancer Therapy. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-70253-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bianchi, Giada, and Kenneth C. Anderson. "Multiple Myeloma." In Targeted Therapy in Translational Cancer Research. John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781118468678.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dicato, Mario A. "Multiple Myeloma." In Side Effects of Medical Cancer Therapy. Springer London, 2012. http://dx.doi.org/10.1007/978-0-85729-787-7_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bianchi, Giada, and Kenneth C. Anderson. "Multiple Myeloma." In The American Cancer Society's Oncology in Practice. John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118592168.ch33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mina, Roberto, and Antonio Palumbo. "Multiple Myeloma." In Management of Hematological Cancer in Older People. Springer London, 2014. http://dx.doi.org/10.1007/978-1-4471-2837-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Multiple myeloma; Breast cancer"

1

Mishima, Yuji, Yasuhito Terui, and Kiyohiko Hatake. "Abstract A015: Intrapatient heterogeneity of multiple myeloma is evenly distributed in multiple myeloma lesions." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1535-7163.targ-17-a015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Thibaud, Santiago, Aaron Etra, Ryan Subaran, et al. "Abstract 868: Heritable cancer mutations in multiple myeloma." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-868.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Corradini, Andrea, Martin Hansen, and Toma Savic. "Measuring the Frailty Index of Multiple Myeloma Cancer Patients." In 10th EAI International Conference on Pervasive Computing Technologies for Healthcare. ACM, 2016. http://dx.doi.org/10.4108/eai.16-5-2016.2263785.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tompkins, Van S., Zhimin Gu, Hongwei Xu, Guido Tricot, Fenghuang Zhan, and Siegfried Janz. "Abstract B38: Targeting FOXM1 in multiple myeloma." In Abstracts: AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities - May 17-20, 2013; Bellevue, WA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.pms-b38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Matsui, William. "Abstract PL3-2: Translating multiple myeloma stem cells." In Abstracts: AACR International Conference on Translational Cancer Medicine--; Mar 21–24, 2010; Amsterdam, The Netherlands. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1078-0432.tcme10-pl3-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Andreotti, Gabriella, Veronique Benhaim-Luzon, Paul Brennan, et al. "Abstract B115: A pooled analysis of smoking and alcohol drinking and risk of multiple myeloma in the International Multiple Myeloma Consortium." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Oct 22-25, 2011; Boston, MA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1940-6207.prev-11-b115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Duma, Narjust, Miguel Gonzalez Velez, Jesus Vera-Aguilera, et al. "Abstract A27: Diversity in multiple myeloma clinical trials." In Abstracts: Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2017; Atlanta, GA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7755.disp17-a27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Anderson, Kenneth. "Abstract IA13: Novel therapeutic targets in multiple myeloma." In Abstracts: AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; São Paulo, Brazil. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1557-3265.tcm17-ia13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kumar, Shaji. "Abstract CN03-03: Therapeutic interventions to prevent progression of MGUS to multiple myeloma." In Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-cn03-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Guillerey, Camille, Lucas Ferrari de Andrade, Slavica Vuckovic, et al. "Abstract B155: Anti-CD137 mAb therapy of multiple myeloma." In Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr15-b155.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Multiple myeloma; Breast cancer"

1

Li, Tianfang. Multiple Aperture Radiation Therapy (MART) to Breast Cancer. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada456141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shou, Zhenyu. Multiple Aperture Radiation Therapy (MART) for Breast Cancer. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada432996.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ott, Jurg. Statistical Genetics Methods for Localizing Multiple Breast Cancer Genes. Defense Technical Information Center, 1996. http://dx.doi.org/10.21236/ada326461.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ott, Jurg. Statistical Genetic Methods for Localizing Multiple Breast Cancer Genes. Defense Technical Information Center, 1995. http://dx.doi.org/10.21236/ada301699.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ott, Jurg. Statistical Genetics Methods for Localizing Multiple Breast Cancer Genes. Defense Technical Information Center, 1997. http://dx.doi.org/10.21236/ada337861.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lauring, Josh. Multiple Cooperating Oncogenes Drive Recurrent Breast Cancer-Associated Chromosomal Amplifications: Creation of Isogenic Human Cell Line Models. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada612716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lauring, Josh. Multiple Cooperating Oncogenes Drive Recurrent Breast Cancer-Associated Chromosomal Amplifications: Creation of Isogenic Human Cell Line Models. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada583983.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Multiple myeloma; Breast cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography